Sensible Biotechnologies
Summary
In a significant market movement during October 2026, Sensible Biotechnologies was the subject of a vc funding. The transaction achieved a gross valuation of £35,401,189. Leading the round was the family office of Christoph Huber, Isomer Capital, Backed VC, In-Q-Tel, Y Combinator, Civilization Ventures, Tim Garnett, KAYA VC, OTB Ventures, Government of Slovakia, European Union, Blueyard Capital, Recode Ventures.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
the family office of Christoph Huber
Lead Investor / Acquirer
Isomer Capital
Lead Investor / Acquirer
Backed VC
Lead Investor / Acquirer
In-Q-Tel
Lead Investor / Acquirer
Y Combinator
Lead Investor / Acquirer
Civilization Ventures
Lead Investor / Acquirer
Tim Garnett
Lead Investor / Acquirer
KAYA VC
Lead Investor / Acquirer
OTB Ventures
Lead Investor / Acquirer
Government of Slovakia
Lead Investor / Acquirer
European Union
Lead Investor / Acquirer
Blueyard Capital
Lead Investor / Acquirer
Recode Ventures
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series A prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in